Other documents

Consolidated Financial Statements as of and for the years ended December 31, 2008 and 2007, and Independent Auditors’ Report.

The master table of the target product profile (TPP), product specifications, relate to the public health impact and suitability of the product. 

Supplementary informational for the target product profile (TPP) including general information, vaccine characteristics relevant to the TPP, contributors and WHO policy documents. 

Minutes from the AMC Independent Assessment Committee (IAC) meeting on 11 December 2008.

Codebook to assess whether a pneumococcal vaccine meets the Pneumococcal AMC Target Product Profile for regional vaccine serotype coverage.

The government is requesting GAVI support to introduce the Hib vaccine as part of pentavalent into the routine immunisation system. The decision for application was made based on WHO's estimate that some 4% of child deaths in Lao PDR occur due to Hib infections.

According to a study, rotavirus causes 10 million cases of diarrhoea in Latin Ameria and the Caribbean each year. Nicaragua aims to make immunisation against rotavirus sustainable in order to reduce child mortality and is requesting GAVI support until 2012.

To view the full contents of this document, you need a later version of the PDF viewer. You can upgrade to the latest version of Adobe Reader from www.adobe.com/products/acrobat/readstep2.html For further support, go to www.adobe.com/support/products/acrreader.html

The government seeks GAVI support to introduce the Hib antigen as part of the pentavalent vaccine into the routine immunisation schedule and thus extend the range of vaccine-preventable diseases children are protected from. The decision was based on the considerable burden from Hib infections, not only through under-five mortality but also through morbidity.

The government is applying for approx. US$ 23 million over two years from GAVI to support the introduction of pneumococcal vaccine into its routine immunisation schedule. Co-financing amounts to approx. US$ 730,000. The application is based on the disease burden and WHO recommendations and is seen as essential to reduce child mortality and morbidity in Yemen. The country's cMYP has been updated accordingly. Yemen is requesting the vaccine in its currently available PCV-7 composition.

Following the successful introduction of GAVI-funded vaccines in previous years, the Congo plans to  introduce pneumococcal vaccine as soon as it becomes available. This decision is based on the number of cases of pneumonia among children and on the epidemiology of the disease in the region.

GAVI Alliance FORMULAIRE POUR LES PROPOSITIONS DES PAYS en vue d’un soutien : VACCIN CONTRE LES INFECTIONS A PNEUMOCOQUE REPUBLIQUE DU CONGO 22 avril 2008 Veuillez retourner une copie signe du prsent document au : Secrtariat de GAVI Alliance; a/s de l’UNICEF, Palais des Nations, 1211 Genve 10, Suisse. Pour toute questi

Cameroon is applying for GAVI support of US$ 15 million to introduce pneumococcal vaccine into their EPI. The government has provided a comprehensive Multi-Year Plan to back this up and is reporting a doubling of the immunisation rate since 2001 when GAVI support started.

GAVI Alliance FORMULAIRE POUR LES PROPOSITIONS DES PAYS : PHASE 2 Demande de soutien pour l’introduction du vaccin contre les infections pneumocoque dans le PEV en 2010 CAMEROUN Mai 2008 Veuillez retourner une copie signe du prsent document au : Secrtariat de GAVI Alliance; a/s de l’UNICEF, Palais des Nations, 1211 Ge

The GAVI support to HSS shall be used to tackle inequities in the distribution of health workforce over the country and in accessibility of basic health services, especially related to immunisation and maternal and child health. This proposal draws from the experience with a previous HSS proposal.

Due to the significant burden of respiratory diseases, Bhutan has made the introduction of the Hib antigen into ist EPI a priority. The government is applying for GAVI support to introce the pentavalent vaccine from 2009. Sustainability of the programme shall be ensured through the creation of the Bhutan Health trust Fund which will slowly take over the funding for immunisation.

Based on WHO's recommendation for Hib vaccine to positively impact child mortality, the Armenian government decided to introduce Hib antigen as component of pentavalent vaccine, this application is endorsed by Inter-Agency Coordinating Committee.

The report was commissioned by the Monitoring & Evaluation Subgroup of the AMC Donor Committee in August 2007. The monitoring and evaluation proposals contained in this report have been designed to enable the effectiveness, efficiency and eventual impact of this pilot AMC to be measured over time and to assist with its effective management.

Minutes from the AMC Independent Assessment Committee (IAC) meeting on 3 November 2008.

Целью Альянса ГАВИ является укрепление здоровья людей во всем мире путем: (i) предоставления вакцин и средств для доставки вакцин населению беднейших стран мира; (ii) содействия исследованиям и разработке вакцин, необходимых в развивающихся странах; и (iii) оказания поддержки в достижении вышеуказанных целей за счет содействия укреплению систем здравоохранения и гражданского общества, способствующего достижению указанных целей в развивающихся странах.

The purpose of the GAVI Alliance is to promote health by: (i) providing vaccines and the means to deliver such vaccines to people in the poorest countries; (ii) facilitating the research and development of vaccines of primary interest to the developing world; and (iii) to provide support in connection with achieving the foregoing purposes by helping to strengthen health care systems and civil societies supporting such purposes in the developing world.

These By-laws shall enter into force after their approval by the Board and the Federal Supervisory Board for Foundations.

El objetivo de la Alianza GAVI es promover la salud mediante: (i) el suministro de vacunas y de los medios para facilitar dichas vacunas a las personas de los países más pobres; (ii) la facilitación de la investigación y el desarrollo de vacunas de interés primordial para los países en vías de desarrollo; y (iii) el ofrecimiento de apoyo en conexión con la consecución de los objetivos anteriores contribuyendo al fortalecimiento de los sistemas de atención sanitaria y las sociedades civiles que apoyan dichos objetivos en los países en vías de desarrollo.

Applied Strategies Consulting Project - Vaccine Investment Strategy - Rabies analysis

Applied Strategies Consulting Project - Vaccine Investment Strategy - Japanese Encephalitis Analysis